desethyloxybutynin has been researched along with Bladder Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, LM; Easthope, SE; Perry, CM | 1 |
| Chancellor, M | 1 |
| Wagg, A | 1 |
| Oki, T; Toma-Okura, A; Yamada, S | 1 |
1 trial(s) available for desethyloxybutynin and Bladder Diseases
| Article | Year |
|---|---|
Transdermal oxybutynin: for overactive bladder.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Benzhydryl Compounds; Cresols; Double-Blind Method; Exanthema; Humans; Mandelic Acids; Middle Aged; Phenylpropanolamine; Time Factors; Tolterodine Tartrate; Urinary Bladder Diseases; Urinary Incontinence; Xerostomia | 2003 |
3 other study(ies) available for desethyloxybutynin and Bladder Diseases
| Article | Year |
|---|---|
Transdermal oxybutynin. A viewpoint by Michael Chancellor.
Topics: Administration, Cutaneous; Delayed-Action Preparations; Erythema; Humans; Mandelic Acids; Pruritus; Urinary Bladder Diseases; Urinary Incontinence | 2003 |
Transdermal oxybutynin. A viewpoint by Adrian Wagg.
Topics: Administration, Cutaneous; Adult; Aged; Delayed-Action Preparations; Humans; Mandelic Acids; Skin; Urinary Bladder Diseases; Urinary Incontinence | 2003 |
Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Male; Mandelic Acids; N-Methylscopolamine; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Saliva; Urinary Bladder Diseases | 2006 |